HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prediction of P-tau/Aβ42 in the cerebrospinal fluid with blood microRNAs in Alzheimer's disease.

AbstractBACKGROUND:
The most common biomarkers of Alzheimer's disease (AD) are amyloid β (Aβ) and tau, detected in cerebrospinal fluid (CSF) or with positron emission tomography imaging. However, these procedures are invasive and expensive, which hamper their availability to the general population. Here, we report a panel of microRNAs (miRNAs) in serum that can predict P-tau/Aβ42 in CSF and readily differentiate AD from other dementias, including vascular dementia (VaD), Parkinson disease dementia (PDD), behavioral variant frontotemporal dementia (bvFTD), and dementia with Lewy body (DLB).
METHODS:
RNA samples were extracted from the participant's blood. P-tau/Aβ42 of CSF was examined for diagnostic purposes. A pilot study (controls, 21; AD, 23), followed by second (controls, 216; AD, 190) and third groups (controls, 153; AD, 151), is used to establish and verify a predictive model of P-tau/Aβ42 in CSF. The test is then applied to a fourth group of patients with different dementias (controls, 139; AD,155; amnestic mild cognitive impairment [aMCI], 55; VaD, 51; PDD, 53; bvFTD, 53; DLB, 52) to assess its diagnostic capacity.
RESULTS:
In the pilot study, 29 upregulated and 31 downregulated miRNAs in the AD group were found. In Dataset 2, these miRNAs were then included as independent variables in the linear regression model. A seven-microRNA panel (miR-139-3p, miR-143-3p, miR-146a-5p, miR-485-5p, miR-10a-5P, miR-26b-5p, and miR-451a-5p) accurately predicted values of P-tau/Aβ42 of CSF. In Datasets 3 and 4, by applying the predicted P-tau/Aβ42, the predictive model successfully differentiates AD from controls and VaD, PDD, bvFTD, and DLB.
CONCLUSIONS:
This study suggests that the panel of microRNAs is a promising substitute for traditional measurement of P-tau/Aβ42 in CSF as an effective biomarker of AD.
AuthorsLongfei Jia, Min Zhu, Jianwei Yang, Yana Pang, Qi Wang, Ying Li, Tingting Li, Fangyu Li, Qigeng Wang, Yan Li, Yiping Wei
JournalBMC medicine (BMC Med) Vol. 19 Issue 1 Pg. 264 (11 15 2021) ISSN: 1741-7015 [Electronic] England
PMID34775974 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2021. The Author(s).
Chemical References
  • Amyloid beta-Peptides
  • Biomarkers
  • MIRN139 microRNA, human
  • MIRN485 microRNA, human
  • MicroRNAs
  • Peptide Fragments
  • amyloid beta-protein (1-42)
  • tau Proteins
Topics
  • Alzheimer Disease (diagnosis, genetics)
  • Amyloid beta-Peptides
  • Biomarkers
  • Humans
  • MicroRNAs (genetics)
  • Peptide Fragments
  • Pilot Projects
  • tau Proteins

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: